Lupin Reports Q2 Net Profit Of ₹11.6 Billion With EBITDA Margin At 27.2%

Market snapshot: Lupin Limited reported its Q2 financial results, highlighted by consolidated net profit of ₹1,160 crore and revenue from operations of ₹7,230 crore. Operating performance reflected an EBITDA margin of 27.2%, compared to 33.22% in the prior-year period.

Data Snapshot

• Consolidated Net Profit stood at ₹1,160 crore compared to ₹1,478 crore in the corresponding quarter last year.
• Revenue from operations reached ₹7,230 crore versus ₹7,048 crore YoY.
• EBITDA was recorded at ₹2,120 crore compared to ₹2,341 crore in the year-ago period.
• EBITDA Margin came in at 27.2% against 33.22% in Q2 of the previous fiscal year.

What's Changed

• Consolidated net profit decreased by ≈21.5% YoY (derived: ₹1,160 crore vs ₹1,478 crore).
• Revenue from operations increased by ≈2.6% YoY (derived: ₹7,230 crore vs ₹7,048 crore).
• EBITDA margin contracted by 602 basis points YoY to 27.2% from 33.22%.

Key Takeaways

• Top-line expansion remained modest with a 2.6% YoY growth in operational revenue.
• Profitability faced pressure as net earnings dropped over 21% relative to the high-base comparative quarter.
• Operating efficiency contracted sharply as EBITDA margin compressed by over 600 basis points.

SAHI Perspective

Lupin's Q2 results highlight a divergence between top-line expansion and underlying profitability. While operational revenue maintained positive momentum, cost pressures and base-effect comparisons in generic drug pricing weighed heavily on operating margins and bottom-line profit execution.

Market Implications

The margin compression to 27.2% may prompt near-term earnings revision across market analysts, likely keeping price action muted until commentary on U.S. generic pricing and R&D spend trajectory provides clarity.

Trading Signals

Market Bias: Bearish

Operating margin compression to 27.2% alongside a 21.5% YoY drop in net profit to ₹1,160 crore creates near-term operational headwinds despite minor revenue growth to ₹7,230 crore.

Underweight: Pharmaceuticals

Trigger Factors:

• Q3 margin recovery trajectory
• U.S. generic pricing dynamics
• R&D spend normalization

Time Horizon: Near-term (0-3 months)

Industry Context

Indian pharmaceutical exporters face dual pressures of pricing erosion in core U.S. generic portfolios alongside rising manufacturing and R&D costs, making operational leverage a critical differentiator.

Key Risks to Watch

• Continued margin compression in core formulations
• Pricing pressure in key export markets
• Higher operational and R&D expenditures

Recent Developments

In Q1 FY27, Lupin achieved quarterly sales exceeding ₹8,000 crore and EBITDA of over ₹2,400 crore, supported by strong performance in U.S. and non-U.S. generic markets.

Closing Insight

Sustaining top-line growth will require Lupin to improve operational efficiency and defend profitability against margin headwinds in subsequent quarters.

High Performance Trading with SAHI.